2020 Dental Pain Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs
The 2020 Dental Pain pipeline report presents a comprehensive overview of the research and development of Dental Pain drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: One drug in Research phase, two drugs in Phase 2 and two drugs in Phase 3
As of February 2020, the Dental Pain pipeline remains robust with 5 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Dental Pain treatment. Diverse types of targeted therapies are being explored through clinical trials including Adrenergic uptake inhibitors; CACNA2D1 protein modulators; calcitonin gene related peptide (CGRP) receptor inhibitor; Cyclo-oxygenase 2 inhibitors; Nav1.7 voltage-gated sodium channel inhibitors; Opioid mu receptor agonists; Serotonin uptake inhibitors; Sodium channel antagonists.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Dental Pain drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
Dental Pain pipeline drugs profiled in the report include- AFA-P03, E-58425 (celecoxib + tramadol), Bupivacaine extended release, funapide (FX301), Pregabalin
As of February 2020, the Dental Pain pipeline remains robust with 5 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Dental Pain treatment. Diverse types of targeted therapies are being explored through clinical trials including Adrenergic uptake inhibitors; CACNA2D1 protein modulators; calcitonin gene related peptide (CGRP) receptor inhibitor; Cyclo-oxygenase 2 inhibitors; Nav1.7 voltage-gated sodium channel inhibitors; Opioid mu receptor agonists; Serotonin uptake inhibitors; Sodium channel antagonists.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Dental Pain drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
- The report scope comprises of both pre-clinical phase and clinical phase development drugs for Dental Pain development
- Dental Pain pipeline compounds and molecules under study by both large scale and small companies are included in the report
- Dental Pain pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered
- Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered
- Further, orphan drug status, fast track designation, different grants awarded and special status for Dental Pain pipeline candidates included
- Business overview and snapshot of all companies involved in Dental Pain pipeline are included
- Latest market and pipeline developments are provided in the report
Dental Pain pipeline drugs profiled in the report include- AFA-P03, E-58425 (celecoxib + tramadol), Bupivacaine extended release, funapide (FX301), Pregabalin
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Dental Pain Condition
2.3 Dental Pain Pipeline Snapshot, 2020
2.4 Companies investing in Dental Pain pipeline therapeutics
2.5 Phase wise Dental Pain Pipeline Candidates
2.6 Most Researched Mechanism of Action of Dental Pain Pipeline Products
2.7 Route of Administration of Dental Pain Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 AfaSci Inc Overview, Contacts and ASD Pipeline Drugs
3.2 Esteve Pharmaceuticals SA Overview, Contacts and ASD Pipeline Drugs
3.3 Nevakar Inc Overview, Contacts and ASD Pipeline Drugs
3.4 Pacira Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.5 Teva Pharmaceutical Industries Ltd Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 AFA-P03 Drug Details
4.1.1 AFA-P03 Current Status
4.1.2 AFA-P03 Drug Overview
4.1.3 AFA-P03 Mechanism of Action
4.1.4 AFA-P03 Licensing/Collaboration Companies
4.1.5 AFA-P03 Clinical Trials
4.2 E-58425 (celecoxib + tramadol) Drug Details
4.2.1 E-58425 (celecoxib + tramadol) Current Status
4.2.2 E-58425 (celecoxib + tramadol) Drug Overview
4.2.3 E-58425 (celecoxib + tramadol) Mechanism of Action
4.2.4 E-58425 (celecoxib + tramadol) Licensing/Collaboration Companies
4.2.5 E-58425 (celecoxib + tramadol) Clinical Trials
4.3 Bupivacaine extended release Drug Details
4.3.1 Bupivacaine extended release Current Status
4.3.2 Bupivacaine extended release Drug Overview
4.3.3 Bupivacaine extended release Mechanism of Action
4.3.4 Bupivacaine extended release Licensing/Collaboration Companies
4.3.5 Bupivacaine extended release Clinical Trials
4.4 funapide (FX301) Drug Details
4.4.1 funapide (FX301) Current Status
4.4.2 funapide (FX301) Drug Overview
4.4.3 funapide (FX301) Mechanism of Action
4.4.4 funapide (FX301) Licensing/Collaboration Companies
4.4.5 funapide (FX301) Clinical Trials
4.5 Pregabalin Drug Details
4.5.1 Pregabalin Current Status
4.5.2 Pregabalin Drug Overview
4.5.3 Pregabalin Mechanism of Action
4.5.4 Pregabalin Licensing/Collaboration Companies
4.5.5 Pregabalin Clinical Trials
5. LATEST DENTAL PAIN PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Dental Pain Condition
2.3 Dental Pain Pipeline Snapshot, 2020
2.4 Companies investing in Dental Pain pipeline therapeutics
2.5 Phase wise Dental Pain Pipeline Candidates
2.6 Most Researched Mechanism of Action of Dental Pain Pipeline Products
2.7 Route of Administration of Dental Pain Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 AfaSci Inc Overview, Contacts and ASD Pipeline Drugs
3.2 Esteve Pharmaceuticals SA Overview, Contacts and ASD Pipeline Drugs
3.3 Nevakar Inc Overview, Contacts and ASD Pipeline Drugs
3.4 Pacira Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.5 Teva Pharmaceutical Industries Ltd Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 AFA-P03 Drug Details
4.1.1 AFA-P03 Current Status
4.1.2 AFA-P03 Drug Overview
4.1.3 AFA-P03 Mechanism of Action
4.1.4 AFA-P03 Licensing/Collaboration Companies
4.1.5 AFA-P03 Clinical Trials
4.2 E-58425 (celecoxib + tramadol) Drug Details
4.2.1 E-58425 (celecoxib + tramadol) Current Status
4.2.2 E-58425 (celecoxib + tramadol) Drug Overview
4.2.3 E-58425 (celecoxib + tramadol) Mechanism of Action
4.2.4 E-58425 (celecoxib + tramadol) Licensing/Collaboration Companies
4.2.5 E-58425 (celecoxib + tramadol) Clinical Trials
4.3 Bupivacaine extended release Drug Details
4.3.1 Bupivacaine extended release Current Status
4.3.2 Bupivacaine extended release Drug Overview
4.3.3 Bupivacaine extended release Mechanism of Action
4.3.4 Bupivacaine extended release Licensing/Collaboration Companies
4.3.5 Bupivacaine extended release Clinical Trials
4.4 funapide (FX301) Drug Details
4.4.1 funapide (FX301) Current Status
4.4.2 funapide (FX301) Drug Overview
4.4.3 funapide (FX301) Mechanism of Action
4.4.4 funapide (FX301) Licensing/Collaboration Companies
4.4.5 funapide (FX301) Clinical Trials
4.5 Pregabalin Drug Details
4.5.1 Pregabalin Current Status
4.5.2 Pregabalin Drug Overview
4.5.3 Pregabalin Mechanism of Action
4.5.4 Pregabalin Licensing/Collaboration Companies
4.5.5 Pregabalin Clinical Trials
5. LATEST DENTAL PAIN PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
